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PERSPECTIVES ON DRUGS 
Synthetic drug   
production in Europe
Estimating the amount of synthetic drugs produced is 
extremely difficult and at present no robust estimates exist for 
Europe. It is possible, however, to describe the main trends 
and developments in this area based on an extrapolation of 
data from seizures, law enforcement intelligence and forensic 
sources. 
I  Europe’s main producer regions
For analytical purposes, synthetic drug production in Europe 
can be viewed as being centred on four main producer regions 
(EMCDDA and Europol, 2013), as set out below.
North-west Europe 
Production in this area is of global significance and 
conducted by organised crime groups operating in the 
Netherlands and, to a lesser extent, Belgium. Historically, 
this region has been important for the supply of both 
amphetamine and MDMA, and is still thought to account for 
most of the MDMA produced in Europe. More recently, some 
methamphetamine production has also been detected and 
this drug appears to be becoming more commonly available. 
Amphetamine and MDMA are frequently manufactured in the 
same facilities, often with the use of the same equipment. 
Production techniques can be relatively sophisticated and 
this is reflected in the fact that this area is also the source 
of production ‘know-how’. Drugs produced in this area 
supply markets throughout Europe, with some products also 
exported to other parts of the world; however, the global 
significance of this area for MDMA production has decreased 
as production capacity has developed elsewhere.  
Europe has a long history of producing and 
consuming synthetic drugs. The region 
remains important today for the production 
of these substances, with manufacture 
taking place for both domestic 
consumption and export to other parts 
of the world. In terms of both production 
and use, three substances dominate the 
European market for synthetic drugs: 
amphetamine (usually the sulphate 
salt), ecstasy-type drugs, especially 
methylenedioxymethamphetamine 
(MDMA),and methamphetamine (usually 
the hydrochloride salt).
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South-east Europe 
Historically, the main synthetic drug produced in this area 
has been amphetamine, indicated by large-scale seizures in 
both Bulgaria and Turkey. In this part of Europe amphetamine 
is usually produced for sale as ‘Captagon’ tablets intended 
for the Middle East, particularly the Arabian Peninsula (1), 
with Bulgarian crime groups in particular now reported to 
be active in large-scale amphetamine production for these 
markets (see EMCDDA and Europol, 2013). Amphetamine 
production also takes place in Turkey, but probably to a lesser 
extent. Some information also exists to suggest the relocation 
of activities from south-east Europe to non-European Union 
(EU) countries in the Balkans, Caucasus and the Middle East. 
An additional new development is suggested by the fact that 
ten methamphetamine production facilities were detected 
in Bulgaria between 2010 and 2012 (Bulgaria Reitox, 2011, 
2012, 2013; EMCDDA and Europol, 2013). Although the 
Bulgarian focal point reports that the dismantled facilities 
were mostly small-scale and their production intended for 
the domestic market, the emergence of methamphetamine 
production in this region represents a cause for concern.
North-east Europe 
Production in this region is largely undertaken by Polish 
and Lithuanian criminal organisations with the lesser 
involvement of groups in Latvia and Estonia. Amphetamine 
and methamphetamine are produced in this area for both 
a growing local market and export, predominantly to Nordic 
countries. This is illustrated by the fact that the main export 
market for amphetamine produced in Poland appears to 
be Sweden and that much of the amphetamine available in 
Finland is supplied from Estonia. Amphetamine production 
in Poland appears to be particularly significant with about 
150 mid-scale production facilities dismantled between 
1995 and 2012. Currently, methamphetamine production in 
this area is thought to be centred on Lithuania — although 
the evidence for this is somewhat limited with the detection 
of only one mid-scale facility (in 2009) — and Poland where 
two methamphetamine production facilities were detected in 
2012 (Poland Reitox, 2013).
Central Europe 
Illicit production of amphetamine and, to a much larger 
extent, methamphetamine has a long history in the 
Czech Republic, where it dates back to the 1970s and the 
communist period. However, production here differs to that 
found in other parts of Europe as it is usually based on small 
kitchen laboratories with limited production runs producing 
small amounts of drugs for personal use or local sale.  
This explains the relatively large number of production sites 
detected in the Czech Republic, with 235 methamphetamine 
‘kitchen labs’ dismantled in 2012 (Czech Republic Reitox, 
2013). Not all production is of this type, however, and 
some medium-sized production facilities have also been 
detected. In addition, a high-purity crystalline form of 
methamphetamine manufactured in the Czech Republic 
has recently emerged on the Czech and German markets. 
Methamphetamine and amphetamine production, again 
mostly on a small scale, also takes place in Germany, where 
out of the 24 illegal labs dismantled in 2012 13 were used to 
produce methamphetamine and 9 amphetamine. In recent 
years amphetamine facilities have also been dismantled in 
Hungary and Slovenia.
I  The challenge of precursors and ‘pre-precursors’ 
The availability of precursors and other chemicals is essential 
for the manufacturing of synthetic drugs. While obtaining 
the appropriate precursor chemicals is an ongoing problem 
for illicit drug producers, ensuring that precursor chemicals 
are not used for drug production is a major concern for 
drug supply reduction efforts. In Europe, the precursors 
most commonly used to manufacture amphetamine, 
methamphetamine and ecstasy-type substances have been 
benzyl methyl ketone (BMK), ephedrine and pseudoephedrine, 
and piperonyl methyl ketone (PMK), respectively (see online 
interactive element). All these precursors are under both 
European and international control. The importance of BMK 
should be noted, as it is a precursor for both amphetamine 
(1 ) Captagon was originally a legal, medical drug based on phenethylline, a stimulant. Nowadays, although the composition of ‘Captagon’ tablets sold on the illicit market 
remains unclear, laboratory analysis indicates that they contain amphetamine as their main active ingredient (Amphetamines and ecstasy: 2008 global ATS assessment, 
United Nations Office on Drugs and Crime, Vienna).
PERSPECTIVES ON DRUGS I Synthetic drug production in Europe
and methamphetamine and it can be synthesised from several 
‘pre-precursor’ chemicals. 
These precursors may be sourced in a variety of ways. 
Pseudoephedrine can be obtained from medicinal 
preparations containing this drug, usually sold in tablet form 
as over-the-counter medicines in many EU countries. It may, 
however, occasionally also be procured in bulk (powder) form. 
BMK and PMK have, on the other hand, historically been 
procured from sources outside the EU, which include the 
Russian Federation and China. Currently, as a result of greater 
international cooperation, BMK and, to an even greater extent, 
PMK (for which there are very few legitimate uses) both now 
appear to be much more difficult to source.
Illicit manufacturers, however, have adapted to these 
shortages and these precursors are now often synthesised/
converted within Europe from imported non-scheduled 
chemicals sometimes referred to as ‘pre-precursors’ and 
‘masked’ (or ‘designer’) precursors. This situation presents 
a challenge to controlling policies, as a greater number 
of chemicals need to be considered, some of which have 
legitimate uses. There is always a risk that as one chemical 
comes under scrutiny, producers will simply switch to an 
alternative ‘pre-precursor’ chemical that can be used for illicit 
drug production (see online interactive element).
I  Significant trends in synthetic drugs production  in Europe
In early 2014, the following trends could be observed.
Methamphetamine 
Until recently, most of the methamphetamine available in 
Europe was both produced and consumed in the Czech 
Republic and, more recently, Slovakia. Since the late 2000s, 
however, it appears that the quantities of methamphetamine 
produced in Europe are increasing; new production areas 
have been noted and the drug seems to be becoming 
more available. The manufacture of the pure crystalline 
form of the drug has also been noted. Intelligence sources 
and the detection of production facilities suggest that 
methamphetamine is now manufactured in the Netherlands 
and Lithuania, and manufacture has been detected recently 
in Bulgaria and Poland. It is possible that this development 
is linked, at least in part, to the successful circumvention 
by traffickers of control measures targeting the importation 
of BMK or its pre-precursors (e.g. APAAN) into Europe (see 
box ‘APAAN, the latest challenge in Europe’). This could also 
mean, however, that illicit producers previously manufacturing 
amphetamine have now diversified into methamphetamine. 
This is a worrying development that deserves careful 
monitoring, as this drug is known to be particularly detrimental 
to public health.
Amphetamine 
The implication of trends in amphetamine production in 
Europe are difficult to interpret, as a decrease in the number of 
production facilities dismantled in the north-west and north-
east regions has been accompanied by an observed increase 
in the production capacity of the facilities dismantled. In the 
Netherlands and Belgium, for example, use of industrial-sized 
equipment in illicit amphetamine production facilities is now 
reported to have resulted in yields of up to 40 kg per batch 
as compared with only 5–8 kg a few years ago. A similar 
development has also been observed in Poland, where typical 
production runs are now estimated to produce around 8 kg 
of the drug. It is probable that producers now rely extensively 
on APAAN (see box ‘APAAN, the latest challenge in Europe’). 
Overall, it appears likely that amphetamine production is 
becoming more centralised and sophisticated with organised 
crime groups able to produce larger volumes and take a more 
dominant share of the market.
Ecstasy 
The information available (2) suggests that ecstasy availability 
dropped sharply in Europe in 2008, reaching a low point in 
2009. At this time, MDMA virtually disappeared from some 
markets and tablets sold as ecstasy often contained other 
synthetic substances. Indicators now suggest that this trend 
is reversing with ecstasy (MDMA) availability increasing 
again from 2010, although, when compared with the early 
2000s, the market still appears not to have fully recovered 
(see ‘Facts and figures’). It seems likely that the relative 
‘drought’ of ecstasy on European markets in 2008–09 was 
caused by successful international cooperation and law 
enforcement efforts in both Europe and Asia that targeted the 
suppliers of the main ecstasy precursor, PMK. The increase 
in ecstasy availability noted since 2010 suggests that illicit 
manufacturers have found ways to procure alternative 
chemicals from which to manufacture MDMA which are likely 
to include PMK glycidate, sassafras oil and other safrole-rich 
oils (see interactive figure). The large MDMA production 
facilities dismantled in Belgium and the Netherlands in 2013 
and early 2014 would appear to confirm this.   
(2 ) Contents of tablets sold as ecstasy; number of seizures and quantities of ecstasy seized; and number of production facilities dismantled.
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The chemical alpha-phenylacetoacetonitrile (APAAN) 
illustrates the ‘cat and mouse game’ that is played 
between illicit producers attempting to gain access to 
precursors and authorities trying to prevent them. APAAN 
is a precursor of BMK and was placed under control in the 
European Union at the end of 2013 (Official Journal of 
the EU, 2013), while in March 2014 the Commission on 
Narcotic Drugs of the United Nations voted unanimously 
in favour of placing APAAN under international control.  
The legitimate uses for APAAN in Europe are very limited, 
and therefore large imports are likely to be intended for 
conversion to BMK.   
 
Since 2009, a large number of APAAN shipments totalling 
multiple tonnes have been seized or stopped in European 
countries including Poland (800 kg seized in 2010–11), 
Bulgaria (940 kg seized in 2012), Germany (500 kg in 
2012), Hungary (3 tonnes in 2012) and Belgium (23 
individual APAAN seizures in 2012). All of the APAAN 
confiscated in Europe originated from China and its main 
destination seemed to be the Netherlands. About 50 tonnes 
of APAAN were seized in the Netherlands or on their way 
to the country between 2011 and 2013. In addition, many 
clandestine facilities converting APAAN into BMK have been 
dismantled in the Netherlands (17 facilities in 2012), as 
well as in Belgium (2 in 2012), Germany (1 in 2012) and 
Poland (1 in 2012). Conversion of APAAN into BMK is a 
hazardous process. Large quantities of acid (hydrochloric, 
sulphuric or phosphoric) are required for the process, which 
can generate toxic fumes and burning and pose a risk of 
explosion and fire. This constitutes a serious health and 
safety risk not only to those producing the drugs, but also to 
law enforcement officers and members of the communities 
where production sites are located. Furthermore, the 
disposal of the waste products from the conversion process 
can result in environmental damage.  
 
On the basis that one litre of APAAN yields an estimated 
0.7 litres of BMK, an additional concern is that several 
tonnes of amphetamine or methamphetamine could have 
been manufactured from the APAAN seized in Europe since 
2010. 
 
Source: Europol 
APAAN, the latest challenge in Europe 
I  Facts and figures 
Estimated number of amphetamine, methamphetamine and 
ecstasy seizures in Europe, 2001–13
Note: Data on the number of drug seizures are not available for France, the  
Netherlands and Poland and are not included in this graph.
Interactive: synthetic drug precursors available on the EMCDDA website:  
emcdda.europa.eu/topics/pods/synthetic-drug-production
I  Interactive element
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